Investigational Medical Therapies for Endometriosis: Current Data and Future Trends

Ran Zhang, Shahryar K Kavoussi, Dan I Lebovic
Seminars in reproductive medicine · 2017 · vol. 35(04) , pp. 318–325 · doi:10.1055/s-0037-1604095 · PMID:29036739 · W2766408611
review OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This review assesses current investigational hormonal and nonhormonal medical therapies for endometriosis based on preclinical and in vitro data, highlighting the need for safety and efficacy evaluation before clinical trials.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-06 ⓘ

This paper is a review of investigational hormonal and nonhormonal medical therapies for endometriosis, synthesizing evidence from in vitro and in vivo animal models of endometriosis as well as experiments using human endometrial and endometriotic cells. It highlights emerging drug classes and targets beyond current mainstays, including approaches such as oral GnRH antagonists, aromatase inhibitors, and other hormone-modulating agents, emphasizing the need to establish safety and efficacy prior to clinical trials. A major limitation is that, as a review, it summarizes preclinical and mechanistic findings rather than providing results from new large-scale clinical outcomes. Relevance to endometriosis: the review’s entire scope is investigational therapies for endometriosis, and it also cites related conditions such as adenomyosis in discussion of hormone signaling (e.g., aromatase expression normalization in endometrium from women with endometriosis, adenomyosis, or leiomyomas), though its main focus is endometriosis drug development.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract Current mainstays of medical therapy for endometriosis preclude fertility or may have unwanted side effects. Therefore, research has been underway to find alternatives to current options which may be applied to future medical treatment. The focus of this review is that of investigational hormonal and nonhormonal medical therapies based on in vitro and in vivo animal models of endometriosis as well as in human endometrial and endometriotic cells in vitro. Assessment of the safety and efficacy of such novel medical treatments have been, and continue to be, necessary prior to clinical trials.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Drugs, Investigational Drugs, Investigational Drugs, Investigational Endometriosis Animals Clinical Trials as Topic Disease Models, Animal Endometriosis Female Forecasting Humans Mice

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (88)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:13.663096+00:00
License: CC0 · commercial use OK